{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T06:27:48Z","timestamp":1788935268711,"version":"build-2803163510"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ijrobp.2020.08.014","type":"journal-article","created":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T02:49:47Z","timestamp":1599360587000},"page":"227-236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer"],"prefix":"10.1016","volume":"110","author":[{"given":"Trevor J.","family":"Royce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayiotis","family":"Mavroidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Falchook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan C.","family":"Sheets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald B.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issam","family":"El Naqa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George X.","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan E.","family":"Nahum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimm","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Yorke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2020.08.014_bib1","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ijrobp.2008.02.073","article-title":"Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer","volume":"72","author":"Al-Mamgani","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib4","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","article-title":"70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial","volume":"80","author":"Beckendorf","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib5","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.2009.25.8475","article-title":"Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from Proton Radiation Oncology Group\/American College of Radiology 95-09","volume":"28","author":"Zietman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","article-title":"Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): An analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib8","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1200\/JCO.2016.70.4189","article-title":"Moderate hypofractionation in high-risk, organ-confined prostate cancer: Final results of a phase III randomized trial","volume":"35","author":"Arcangeli","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib9","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ijrobp.2014.01.015","article-title":"Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: Results from a randomized trial","volume":"88","author":"Hoffman","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib10","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.ijrobp.2010.07.1984","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: Final results of phase III randomized trial","volume":"81","author":"Yeoh","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib11","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib12","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): Final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib13","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1200\/JCO.2005.06.153","article-title":"Randomized trial comparing two fractionation schedules for patients with localized prostate cancer","volume":"23","author":"Lukka","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib14","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib15","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib16","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib17","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1200\/JCO.2016.67.3764","article-title":"Making radiation therapy for prostate cancer more economical and more convenient","volume":"34","author":"Zietman","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.semradonc.2017.02.006","article-title":"Stereotactic body radiotherapy for low- and intermediate-risk prostate cancer","volume":"27","author":"Kishan","year":"2017","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.prro.2018.01.002","article-title":"Stereotactic body radiation therapy for high-risk prostate cancer: Not ready","volume":"8","author":"Royce","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib20","doi-asserted-by":"crossref","unstructured":"Widmark A, Gunnlaugsson A, Beckman L. Ultrahypofractionation for prostate cancer: Outcome from the Scandinavian phase 3 HYPO-RT-PC trial. Paper presented at: European Society for Radiotherapy and Oncology Conference, Barcelona, Spain. April 20-24, 2018.","DOI":"10.1016\/S0167-8140(18)30909-5"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib21","first-page":"1009","article-title":"Is the \u03b1\/\u03b2 ratio for prostate tumours really low and does it vary with the level of risk at diagnosis?","volume":"33","author":"Fowler","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.euf.2017.10.011","article-title":"Conventional versus hypofractionated radiation therapy for localized prostate cancer: A meta-analysis of randomized noninferiority trials","volume":"5","author":"Royce","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib23","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ijrobp.2017.07.021","article-title":"Conventional versus hypofractionated radiotherapy in localized or locally advanced prostate cancer: A systematic review and meta-analysis along with therapeutic implications","volume":"99","author":"Datta","year":"2017","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib24","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib25","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0360-3016(02)04470-X","article-title":"Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: Descriptions and implications","volume":"56","author":"Stock","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib26","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/cncr.22183","article-title":"Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: A multiinstitutional pooled analysis","volume":"107","author":"Horwitz","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib27","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2018.01.014","article-title":"ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer","volume":"127","author":"Salembier","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00066-002-0907-x","article-title":"Interobserver comparison of CT and MRI-based prostate apex definition. Clinical relevance for conformal radiotherapy treatment planning","volume":"178","author":"Wachter","year":"2002","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib30","doi-asserted-by":"crossref","first-page":"S718","DOI":"10.1016\/j.ijrobp.2013.06.1901","article-title":"CT-MRI fusion uncertainty in prostate treatment planning for different image guidance techniques","volume":"87","author":"Chen","year":"2013","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib31","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.ijrobp.2006.11.027","article-title":"Prostate volume contouring: A 3D analysis of segmentation using 3DTRUS, CT, and MR","volume":"67","author":"Smith","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib32","doi-asserted-by":"crossref","first-page":"264","DOI":"10.5489\/cuaj.3236","article-title":"Prostate volume estimations using magnetic resonance imaging and transrectal ultrasound compared to radical prostatectomy specimens","volume":"10","author":"Paterson","year":"2016","journal-title":"J Can Urol Assoc"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib33","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/j.prro.2019.06.009","article-title":"Comparison of motion-insensitive T2-weighted MRI pulse sequences for visualization of the prostatic urethra during MR simulation","volume":"9","author":"Zakian","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jmrs.205","article-title":"First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: Early PSA response, acute toxicity and quality of life","volume":"64","author":"Dixit","year":"2017","journal-title":"J Med Radiat Sci"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib35","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/mp.12830","article-title":"Changes in prostate orientation due to removal of a Foley catheter","volume":"45","author":"Litzenberg","year":"2018","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib36","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ijrobp.2006.02.039","article-title":"Clinicopathologic analysis of extracapsular extension in prostate cancer: Should the clinical target volume be expanded posterolaterally to account for microscopic extension?","volume":"65","author":"Chao","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.radonc.2018.03.005","article-title":"Dose escalation for prostate stereotactic ablative radiotherapy (SABR): Late outcomes from two prospective clinical trials","volume":"127","author":"Alayed","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib38","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0936-6555(05)80598-9","article-title":"Radical external beam radiotherapy for localized carcinoma of the prostate using a hypofractionation technique","volume":"3","author":"Collins","year":"1991","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib39","first-page":"e395","article-title":"Stereotactic body radiotherapy for clinically localized prostate cancer: Toxicity and biochemical disease-free outcomes from a multi-institutional patient registry","volume":"7","author":"Davis","year":"2015","journal-title":"Cureus"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2014.00369","article-title":"Multi-institutional registry for prostate cancer radiosurgery: A prospective observational clinical trial","volume":"4","author":"Freeman","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib41","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1002\/cncr.26699","article-title":"Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: Preliminary results of a multi-institutional phase 1 feasibility trial","volume":"118","author":"McBride","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib42","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2016.02.014","article-title":"Stereotactic body radiation therapy for low and intermediate risk prostate cancer\u2014Results from a multi-institutional clinical trial","volume":"59","author":"Hannan","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.prro.2017.08.004","article-title":"A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life","volume":"8","author":"Jackson","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib44","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.clon.2014.08.007","article-title":"Prostate stereotactic body radiotherapy\u2014First UK experience","volume":"26","author":"Tree","year":"2014","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib45","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/153303460900800509","article-title":"Stereotactic body radiotherapy: An emerging treatment approach for localized prostate cancer","volume":"8","author":"Friedland","year":"2009","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib46","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fonc.2014.00279","article-title":"A phase II trial of stereotactic ablative body radiotherapy for low-risk prostate cancer using a non-robotic linear accelerator and real-time target tracking: Report of toxicity, quality of life, and disease control outcomes with 5-year minimum follow-up","volume":"4","author":"Mantz","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2014.00321","article-title":"Virtual HDR CyberKnife SBRT for localized prostatic carcinoma: 5-year disease-free survival and toxicity observations","volume":"4","author":"Fuller","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib48","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fonc.2016.00168","article-title":"Predicting biochemical disease-free survival after prostate stereotactic body radiotherapy: Risk-stratification and patterns of failure","volume":"6","author":"Katz","year":"2016","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib49","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00066-016-0971-2","article-title":"SHARP hypofractionated stereotactic radiotherapy is well tolerated Toxicity and quality of life assessment","volume":"192","author":"Rucinska","year":"2016","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib50","first-page":"1007","article-title":"Cyberknife radioablation of prostate cancer\u2014Preliminary results for 400 patients","volume":"18","author":"Miszczyk","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib51","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ijrobp.2006.10.050","article-title":"Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results","volume":"67","author":"Madsen","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-717X-8-84","article-title":"Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: Early results","volume":"8","author":"Aluwini","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib53","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2490-13-49","article-title":"A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy","volume":"13","author":"Bolzicco","year":"2013","journal-title":"BMC Urol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-717X-8-58","article-title":"Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: The Georgetown University experience","volume":"8","author":"Chen","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib55","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/j.clon.2016.06.013","article-title":"High-quality linac-based stereotactic body radiation therapy with flattening filter free beams and volumetric modulated Arc therapy for low-intermediate risk prostate cancer. A mono-institutional experience with 90 patients","volume":"28","author":"D\u2019Agostino","year":"2016","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib56","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1080\/0284186X.2017.1288923","article-title":"Hypofractionated stereotactic body radiotherapy for localized prostate cancer\u2014First Nordic clinical experience","volume":"56","author":"Koskela","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-015-0488-3","article-title":"Sexual, irritative, and voiding outcomes, following stereotactic body radiation therapy for prostate cancer","volume":"10","author":"Rana","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib58","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0022-5347(05)64282-6","article-title":"Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer","volume":"168","author":"Rosser","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib59","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2420786","article-title":"Evolving paradigm of radiotherapy for high-risk prostate cancer: Current consensus and continuing controversies","volume":"2016","author":"Juloori","year":"2016","journal-title":"Prostate Cancer"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib60","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","article-title":"Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer","volume":"82","author":"King","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib61","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/030089161109700109","article-title":"Image-guided stereotactic body radiation therapy for localized prostate cancer","volume":"97","author":"Kang","year":"2011","journal-title":"Tumori"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib62","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fonc.2014.00312","article-title":"SBRT for the primary treatment of localized prostate cancer: The effect of Gleason score, dose and heterogeneity of intermediate risk on outcome utilizing 2.2014 NCCN risk stratification guidelines","volume":"4","author":"Bernetich","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib63","series-title":"Radiobiology for the Radiologist","author":"Hall","year":"2011"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib64","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","article-title":"Fractionation and protraction for radiotherapy of prostate carcinoma","volume":"43","author":"Brenner","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib65","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/09553009214552071","article-title":"Tumour and normal tissue responses to fractionated non-uniform dose delivery","volume":"62","author":"K\u00e4llman","year":"1992","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib66","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1120\/jacmp.v5i1.1970","article-title":"A TCP-NTCP estimation module using DVHs and known radiobiological models and parameter sets","volume":"5","author":"Warkentin","year":"2004","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib67","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1016\/j.prro.2015.04.009","article-title":"High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment","volume":"5","author":"Fuller","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib68","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13014-017-0833-9","article-title":"Salvage robotic SBRT for local prostate cancer recurrence after radiotherapy: Preliminary results of the Oscar Lambret Center","volume":"12","author":"Leroy","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib70","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fonc.2017.00005","article-title":"Intensity-modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: A report on 3-year toxicity","volume":"7","author":"Paydar","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib71","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.prro.2017.11.008","article-title":"Stereotactic body radiotherapy (SBRT) for high-risk prostate cancer: Where are we now?","volume":"8","author":"Gonzalez-Motta","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib72","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ijrobp.2014.03.012","article-title":"Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer","volume":"89","author":"Kim","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib74","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.semradonc.2016.08.008","article-title":"Advances in prostate cancer magnetic resonance imaging and positron emission tomography-computed tomography for staging and radiotherapy treatment planning","volume":"27","author":"Moghanaki","year":"2017","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib75","article-title":"ICRU Report 91: Prescribing, recording, and reporting of stereotactic treatments with small photon beams","volume":"14","year":"2014","journal-title":"J ICRU"},{"key":"10.1016\/j.ijrobp.2020.08.014_bib77","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5173\/ceju.2015.582","article-title":"CyberKnife-based prostate cancer patient radioablation\u2014Early results of irradiation in 200 patients","volume":"68","author":"Miszczyk","year":"2015","journal-title":"Cent Eur J Urol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162034102X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162034102X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:53:12Z","timestamp":1759744392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030162034102X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S036030162034102X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2020.08.014","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2020.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}